This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ariza, J Articles by Fernández-Viladrich, P Search for Related Content PubMed PubMed Citation Articles by Ariza, J Articles by Fernández-Viladrich, P

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 October; 28(4): 548-551

Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.

J Ariza, F Gudiol, R Pallarés, G Rufí and P Fernández-Viladrich

ABSTRACT

In an attempt to compare the efficacy of rifampin-doxycycline with tetracycline-streptomycin for the treatment of human brucellosis, we administered both combinations for a 30-day period, similar to the period recommended by the World Health Organization in a prospective, randomized trial. Forty-six patients were included in the final study (36 men and 10 women); 41 had blood cultures positive for Brucella melitensis. The 28 patients in group A received tetracycline hydrochloride at doses of 0.5 g every 6 h or doxycycline at 100 mg every 12 h for 30 days plus 1 g of streptomycin a day for 21 days. The 18 patients in group B received rifampin at 15 mg/kg per day in a single morning dose plus 100 mg of doxycycline every 12 h for 30 days. For patients with focal disease from both groups, therapy was prolonged to 45 days. All patients underwent rigorous clinical and bacteriological long-term follow-up. There were no therapeutic failures in either group, and the defervescence period was similar for both groups (3.1 days for group A, 2.6 days for group B). Two patients (7.1%) from group A had relapses, as did seven (38.8%) from group B (P = 0.024), and blood cultures again became positive for B. melitensis in all of them. In both groups treatment was generally well tolerated. The results strongly suggest that the rifampin-doxycycline combination is a less efficacious mode of therapy for brucellosis to prevent relapses than is the classical tetracycline-streptomycin combination when both are administered for 30 days. A more prolonged period of administration of the rifampin-doxycycline combination may be required to obtain the same low relapse rate as that achieved with the classical tetracycline-streptomycin treatment.

---

Antimicrob Agents Chemother. 1985 October; 28(4): 548-551

This article has been cited by other articles:

• MAAS, K. S. J. S. M., MENDEZ, M., ZAVALETA, M., MANRIQUE, J., FRANCO, M. P., MULDER, M., BONIFACIO, N., CASTANEDA, M. L., CHACALTANA, J., YAGUI, E., GILMAN, R. H., GUILLEN, A., BLAZES, D. L., ESPINOSA, B., HALL, E., ABDOEL, T. H., SMITS, H. L., THE BRUCELLOSIS WORKING GROUP IN CALLAO, (2007). EVALUATION OF BRUCELLOSIS BY PCR AND PERSISTENCE AFTER TREATMENT IN PATIENTS RETURNING TO THE HOSPITAL FOR FOLLOW-UP. Am J Trop Med Hyg 76: 698-702 [Abstract] [Full Text]  
• Ariza, J., Gudiol, F., Pallares, R., Viladrich, P. F., Rufi, G., Corredoira, J., Miravitlles, M. R. (1992). Treatment of Human Brucellosis with Doxycycline plus Rifampin or Doxycycline plus Streptomycin: A Randomized, Double-Blind Study. ANN INTERN MED 117: 25-30 [Abstract]  
• Ariza, J., Servitje, O., Pallares, R., Viladrich, P. F., Rufi, G., Peyri, J., Gudiol, F. (1989). Characteristic Cutaneous Lesions in Patients With Brucellosis. Arch Dermatol 125: 380-383 [Abstract]